CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.
CASI stock price ended at $0 on 日曜日, after dropping NaN%
On the latest trading day Jun 21, 2026, the stock price of CASI fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for CASI decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.